PubRank

R A Rudick

Author PubWeight™ 101.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 1996 10.39
2 Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 4.41
3 Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011 4.25
4 The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999 3.71
5 Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995 3.06
6 The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 2.17
7 Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998 1.97
8 Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002 1.78
9 Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 1999 1.73
10 Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997 1.66
11 Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002 1.61
12 Multiple sclerosis. The spectrum of severity. Arch Neurol 1983 1.54
13 Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001 1.53
14 Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007 1.45
15 Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001 1.44
16 Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005 1.43
17 Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000 1.39
18 A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999 1.24
19 Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985 1.21
20 Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000 1.18
21 The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990 1.13
22 T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 2002 1.12
23 Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010 1.10
24 The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995 1.09
25 A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. J Behav Med 1997 1.08
26 Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000 1.07
27 Diagnostic criteria for multiple sclerosis research involving multiply affected families. Arch Neurol 1991 1.06
28 Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005 1.05
29 Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008 1.03
30 Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J Neurosci Methods 1982 1.02
31 Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005 1.01
32 Recovery from the 'locked-in' syndrome. Arch Neurol 1982 1.00
33 Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000 0.97
34 A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000 0.96
35 Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol 1986 0.95
36 Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010 0.94
37 Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989 0.93
38 Asymptomatic intracerebral hematoma as an incidental finding. Arch Neurol 1981 0.93
39 A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995 0.92
40 Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). Mult Scler 2000 0.92
41 A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000 0.91
42 Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artifact? Arch Neurol 1992 0.90
43 Free kappa light chains in multiple sclerosis spinal fluid. Ann Neurol 1986 0.88
44 Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology 1985 0.88
45 Free light chains in multiple sclerosis and infections of the CNS. Neurology 1987 0.84
46 Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991 0.84
47 Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996 0.84
48 Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells. J Immunol 1986 0.84
49 Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. AJNR Am J Neuroradiol 1987 0.83
50 Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001 0.83
51 The use of brain magnetic resonance imaging in multiple sclerosis. Arch Neurol 1994 0.83
52 Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma. J Neurol Neurosurg Psychiatry 1997 0.82
53 Corpus callosum and subcallosal-periventricular lesions in multiple sclerosis: detection with MR. Radiology 1986 0.82
54 Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult Scler 2008 0.82
55 Pulmonary function and dysfunction in multiple sclerosis. Arch Neurol 1988 0.81
56 Integrity of blood-brain barrier to peroxidase in senescent mice. Neurobiol Aging 1983 0.81
57 Optimal reference population for the multiple sclerosis functional composite. Mult Scler 2007 0.80
58 Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trial. Appl Nurs Res 1996 0.80
59 Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996 0.80
60 Using an automated recruitment process to generate an unbiased study sample of multiple sclerosis patients. Telemed J E Health 2010 0.80
61 Enhanced vascular permeability in acute disseminated vasculomyelinopathy. Ann Neurol 1981 0.80
62 Neuropathological features of a lupus-like disorder in autoimmune mice. Ann Neurol 1983 0.80
63 Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. Mult Scler 2011 0.80
64 Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. Online J Curr Clin Trials 1992 0.79
65 High-signal periventricular lesions in patients with sarcoidosis: neurosarcoidosis or multiple sclerosis? AJR Am J Roentgenol 1989 0.79
66 Experimental therapies for multiple sclerosis: current status. Cleve Clin J Med 1992 0.79
67 Sensitive competitive-binding ELISAs for quantifying free kappa and lambda light chains in cerebrospinal fluid. J Clin Lab Anal 1991 0.79
68 Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1998 0.79
69 Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis. AJNR Am J Neuroradiol 2014 0.79
70 Simultaneous determination of cerebrospinal fluid oligoclonal bands and the "gamma-protein index" by agarose electrophoresis and densitometry. Clin Chem 1986 0.78
71 Stereotactic biopsy of an active multiple sclerosis lesion. Immunocytochemical analysis and neuropathologic correlation with magnetic resonance imaging. Arch Neurol 1990 0.78
72 Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. J Neuroimmunol 1992 0.78
73 Stereotactic biopsy of non-neoplastic lesions in adults. Cleve Clin J Med 1992 0.77
74 Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1q. Arch Neurol 1985 0.77
75 Advances in specific therapy for multiple sclerosis. Curr Opin Neurol 1994 0.77
76 Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol 1990 0.76
77 Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing--remitting multiple sclerosis patients. Mult Scler 2005 0.76
78 Pregnancy and multiple sclerosis. Arch Neurol 1995 0.76
79 Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997. Neurology 2001 0.76
80 Volume T1-weighted gradient echo MRI in multiple sclerosis patients. J Comput Assist Tomogr 1992 0.75
81 Heat-shock proteins and autoimmunity: implications for multiple sclerosis. Ann Neurol 1993 0.75
82 How does one define progression of disease in patients with relapsing-remitting multiple sclerosis? Arch Neurol 2000 0.75
83 Corticosteroids and optic neuritis. Neurology 1993 0.75
84 The value of brain magnetic resonance imaging in multiple sclerosis. Arch Neurol 1992 0.75
85 Isolation of model soluble immune complexes in the fluid phase by monoclonal anti-IgG-ferritin antibodies. Scand J Immunol 1985 0.75
86 The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol 1987 0.75
87 Preparation of monoclonal antibody-ferritin conjugates of high specific activity. Histochemistry 1984 0.75
88 The morphology of murine cerebral ventriculosubarachnoid space I. Light microscopy. Brain Res Bull 1981 0.75
89 Betaseron for multiple sclerosis. Implications for therapeutics. Arch Neurol 1994 0.75
90 Which test for multiple sclerosis? Cleve Clin J Med 1989 0.75
91 Isolated idiopathic optic neuritis. Analysis of free kappa-light chains in cerebrospinal fluid and correlation with nuclear magnetic resonance findings. Arch Neurol 1986 0.75
92 Psychologic aspects of multiple sclerosis. N Y State J Med 1983 0.75
93 A 29-year-old renal transplant patient with multiple brain lesions. Cleve Clin J Med 1989 0.75
94 Normal pressure hydrocephalus: a treatable dementia. Tex Med 1980 0.75
95 Recovery from the locked-in syndrome. Trans Am Neurol Assoc 1980 0.75
96 Prescribing recommendations for interferon-Beta in multiple sclerosis. CNS Drugs 1997 0.75